Eli Lil­ly tasks Nim­bus with hit­ting a 'high-val­ue' tar­get for di­a­betes, obe­si­ty

The com­pu­ta­tion­al chem­istry ex­perts at Nim­bus have al­ways tak­en pride in se­lect­ing com­pelling tar­gets and de­ploy­ing a struc­ture-based ap­proach to drug them. Eli Lil­ly is now swoop­ing in to part­ner on one such tar­get.

In a $496 mil­lion deal — which cov­ers re­search fund­ing as well as mile­stones — Lil­ly wants Nim­bus to come up with iso­form-se­lec­tive small mol­e­cule ac­ti­va­tors of AMPK. Find­ing the right way to ac­ti­vate AMPK, the com­pa­nies say, can open the door to new treat­ments for di­a­betes, obe­si­ty and re­lat­ed dis­or­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER